|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.850 USD | -3.39% |
|
+0.62% | +70.18% |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Chart: Technical Analysis
Stock exchange
Nasdaq
ORMP 4.850 $
-3.39%
1.24M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| ORMP | 4.850USD | -3.39% | 1.24M $ | |
CBOE
| ORMP | 4.845USD | -3.68% | 33.72K $ | |
|
Börse Stuttgart
| OJU1 | 4.140EUR | -3.72% | 16.56K € | |
|
Tradegate
| OJU1 | 4.185EUR | -3.35% | 1.67K € | |
|
TEL AVIV STOCK EXCHANGE
| ORMP | 1,528.00ILa | +2.34% | 608K ILa | |
|
Deutsche Boerse AG
| OJU1 | 4.255EUR | -0.58% | 0 € | |
|
Boerse Muenchen
| OJU1 | 4.225EUR | -1.52% | 0 € |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 5.34 | 5.34 | 5.03 |
| Spread/Res. | -9.18% | -9.18% | -3.58% |
| Spread/Supp. | +2.54% | +15.48% | +46.53% |
| Support | 4.73 | 4.2 | 3.31 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ORMP Stock
- Charts Oramed Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
